MRK Latest Press Releases

-- October 1, 2026 --

Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29 Business Wire 6:45 AM

-- September 30, 2026 --

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) Business Wire 8:15 AM

-- September 28, 2026 --

CAPVAXIVE Included in Ontario's Publicly Funded Adult Pneumococcal Immunization Program PRNewswire 8:01 AM

Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor Business Wire 6:45 AM

-- September 25, 2026 --

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn Business Wire 4:30 PM

U.S. FDA Approves WELIREG (belzutifan) Plus LENVIMA (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Business Wire 6:45 AM

-- September 24, 2026 --

Merck's Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema Business Wire 6:45 AM

-- September 22, 2026 --

U.S. FDA Approves Update to the Label for WINREVAIR (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Business Wire 6:45 AM

-- September 21, 2026 --

Merck Canada Partners with the Montreal Museum of Fine Arts to Present the North American Premiere of Chiharu Shiota: The Soul Trembles PRNewswire 9:00 AM

Merck's KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA (pembrolizumab) Indications Approved in Japan Business Wire 6:45 AM

-- September 18, 2026 --

Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) Business Wire 6:55 AM

Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV Business Wire 6:45 AM

-- September 14, 2026 --

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda (Pembrolizumab) in FAP-a Positive Solid Tumors Globe Newswire 6:16 AM

-- September 10, 2026 --

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market Globe Newswire 8:30 AM

-- September 8, 2026 --

Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference Business Wire 6:45 AM

-- September 2, 2026 --

Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference Business Wire 6:45 AM

-- August 19, 2026 --

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma Business Wire 6:45 AM

-- August 6, 2026 --

U.S. FDA Accepts sBLA for ENFLONSIA (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season Business Wire 6:45 AM

-- August 5, 2026 --

Health Canada Approves KEYTRUDA for the treatment of adult patients with muscle invasive bladder cancer who are ineligible for cisplatin containing chemotherapy, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment PRNewswire 11:00 AM

-- August 4, 2026 --

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline Business Wire 6:30 AM

-- July 29, 2026 --

Merck Announces Fourth-Quarter 2026 Dividend Business Wire 11:04 AM

-- July 24, 2026 --

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development Business Wire 6:45 AM

-- July 23, 2026 --

Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer PRNewswire 1:01 PM

-- July 21, 2026 --

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy Business Wire 10:00 AM

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure Business Wire 10:00 AM

-- July 16, 2026 --

Merck's LIPFENDRA (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia Business Wire 6:45 AM

-- July 15, 2026 --

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026 Business Wire 7:00 AM

KEYTRUDA (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire 6:45 AM

-- July 10, 2026 --

FDA Approves KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC) Business Wire 2:10 PM

-- July 1, 2026 --

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4 Business Wire 6:45 AM

-- June 29, 2026 --

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV Business Wire 6:45 AM

-- June 25, 2026 --

FDA Approves KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS =10) Advanced Triple-Negative Breast Cancer (TNBC) Business Wire 6:45 AM

-- June 24, 2026 --

The Quest to Repair What Multiple Sclerosis Takes Away Globe Newswire 8:30 AM

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market Globe Newswire 8:30 AM

European Commission Approves KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer Business Wire 6:45 AM

-- June 22, 2026 --

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) Business Wire 6:45 AM

-- June 18, 2026 --

U.S. FDA Approves an Additional Indication for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease Business Wire 6:45 AM

-- June 17, 2026 --

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages Business Wire 6:45 AM

-- June 12, 2026 --

FDA Approves KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC) Business Wire 4:10 PM

-- June 11, 2026 --

Merck Animal Health to Acquire TARGAN Business Wire 6:45 AM

-- June 8, 2026 --

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment Business Wire 4:35 PM

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study Business Wire 4:30 PM

-- June 3, 2026 --

Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity PRNewswire 9:00 AM

-- June 2, 2026 --

Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference Business Wire 6:45 AM

-- June 1, 2026 --

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting ACCESS Newswire 8:00 AM

-- May 29, 2026 --

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) Business Wire 6:45 AM

-- May 28, 2026 --

Merck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to Care PRNewswire 9:00 AM

Merck to Participate in the Jefferies Global Healthcare Conference Business Wire 6:45 AM

-- May 26, 2026 --

Merck Announces Third-Quarter 2026 Dividend Business Wire 1:28 PM

-- May 22, 2026 --

Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer Business Wire 7:55 AM

-- May 18, 2026 --

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire 6:45 AM

-- May 13, 2026 --

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities Globe Newswire 8:30 AM

-- May 12, 2026 --

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026 Business Wire 6:45 AM

-- May 7, 2026 --

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate Business Wire 2:05 PM

-- May 6, 2026 --

Merck Animal Health Selects Salesforce's Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees Business Wire 9:00 AM

-- May 5, 2026 --

Merck Completes Acquisition of Terns Pharmaceuticals, Inc. Business Wire 8:45 AM